In conclusion, our retrospective study found that individualized selection of chemotherapy drugs combined with sequential immunotherapy based on BRCA1 mRNA expression level could control the disease and prolong survival of patients with unresectable pancreatic cancer. Here, BRCA1 is linked to familial pancreatic carcinoma.